{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:16:55Z","timestamp":1789913815154,"version":"4.0.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s11882-019-0844-8","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T05:05:11Z","timestamp":1551330311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Emerging Therapeutics for Ocular Surface Disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Leonard","family":"Bielory","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dovid","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"844_CR1","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1517\/14728210903103818","volume":"14","author":"C Origlieri","year":"2009","unstructured":"Origlieri C, Bielory L. Emerging drugs for conjunctivitis. Expert Opin Emerg Drugs. 2009;14:523\u201336.","journal-title":"Expert Opin Emerg Drugs"},{"key":"844_CR2","first-page":"485","volume":"18","author":"S Butrus","year":"2005","unstructured":"Butrus S, Portela R. Ocular allergy: diagnosis and treatment. Ophthalmol Clin N Am. 2005;18:485\u201392 v.","journal-title":"Ophthalmol Clin N Am"},{"key":"844_CR3","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jaci.2010.06.050","volume":"126","author":"K Singh","year":"2010","unstructured":"Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol. 2010;126:778\u201383 e776.","journal-title":"J Allergy Clin Immunol"},{"key":"844_CR4","first-page":"49","volume":"32","author":"M Sacchetti","year":"2018","unstructured":"Sacchetti M, Abicca I, Bruscolini A, Cavaliere C, Nebbioso M, Lambiase A. Allergic conjunctivitis: current concepts on pathogenesis and management. J Biol Regul Homeost Agents. 2018;32:49\u201360.","journal-title":"J Biol Regul Homeost Agents"},{"key":"844_CR5","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2500\/aap.2013.34.3695","volume":"34","author":"L Bielory","year":"2013","unstructured":"Bielory L, Meltzer EO, Nichols KK, Melton R, Thomas RK, Bartlett JD. An algorithm for the management of allergic conjunctivitis. Allergy Asthma Proc. 2013;34:408\u201320.","journal-title":"Allergy Asthma Proc"},{"key":"844_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2013.08.007","volume":"121","author":"PS Bilkhu","year":"2014","unstructured":"\u2022\u2022 Bilkhu PS, Wolffsohn JS, Naroo SA, Robertson L, Kennedy R. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. Ophthalmology. 2014;121:72\u20138 Sheds light on effectiveness of cold compresses and lubricant based treatments with or without a topical pharmacological agent.","journal-title":"Ophthalmology"},{"key":"844_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/archopht.1990.01070060068051","volume":"108","author":"MB Abelson","year":"1990","unstructured":"Abelson MB, Paradis A, George MA, Smith LM, Maguire L, Burns R. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis. Arch Ophthalmol. 1990;108:520\u20134.","journal-title":"Arch Ophthalmol"},{"key":"844_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/0091-6749(94)90081-7","volume":"94","author":"SL Spector","year":"1994","unstructured":"Spector SL, Raizman MB. Conjunctivitis medicamentosa. J Allergy Clin Immunol. 1994;94:134\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"844_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/OPX.0000000000001182","volume":"95","author":"E McLaurin","year":"2018","unstructured":"\u2022\u2022 McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. Brimonidine ophthalmic solution 0.025% for reduction of ocular redness: a randomized clinical trial. Optom Vis Sci. 2018;95:264\u201371 A potential ophthalmic decongestant showing minimal rebound phenomena of the ocular surface when used over 4 weeks.","journal-title":"Optom Vis Sci"},{"key":"844_CR10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/02713683.2017.1381269","volume":"43","author":"GL Torkildsen","year":"2018","unstructured":"Torkildsen GL, Sanfilippo CM, DeCory HH, Gomes PJ. Evaluation of efficacy and safety of brimonidine tartrate ophthalmic solution, 0.025% for treatment of ocular redness. Curr Eye Res. 2018;43:43\u201351.","journal-title":"Curr Eye Res"},{"key":"844_CR11","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1097\/ICO.0000000000001310","volume":"36","author":"VM Rathi","year":"2017","unstructured":"Rathi VM, Taneja M, Dumpati S, Mandathara PS, Sangwan VS. Role of scleral contact lenses in management of coexisting keratoconus and Stevens-Johnson syndrome. Cornea. 2017;36:1267\u20139.","journal-title":"Cornea"},{"key":"844_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.iac.2007.11.002","volume":"28","author":"MA Lemp","year":"2008","unstructured":"Lemp MA, Bielory L. Contact lenses and associated anterior segment disorders: dry eye disease, blepharitis, and allergy. Immunol Allergy Clin N Am. 2008;28:105\u201317 vi-vii.","journal-title":"Immunol Allergy Clin N Am"},{"key":"844_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cis.2015.08.002","volume":"233","author":"S Gause","year":"2016","unstructured":"\u2022\u2022 Gause S, Hsu KH, Shafor C, Dixon P, Powell KC, Chauhan A. Mechanistic modeling of ophthalmic drug delivery to the anterior chamber by eye drops and contact lenses. Adv Colloid Interf Sci. 2016;233:139\u201354 Novel drug delivery system.","journal-title":"Adv Colloid Interf Sci"},{"key":"844_CR14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.actbio.2016.05.032","volume":"41","author":"C Gonzalez-Chomon","year":"2016","unstructured":"Gonzalez-Chomon C, Silva M, Concheiro A, Alvarez-Lorenzo C. Biomimetic contact lenses eluting olopatadine for allergic conjunctivitis. Acta Biomater. 2016;41:302\u201311.","journal-title":"Acta Biomater"},{"key":"844_CR15","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/OPX.0b013e3182639dc8","volume":"89","author":"A Soluri","year":"2012","unstructured":"Soluri A, Hui A, Jones L. Delivery of ketotifen fumarate by commercial contact lens materials. Optom Vis Sci. 2012;89:1140\u20139.","journal-title":"Optom Vis Sci"},{"key":"844_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1167\/tvst.7.2.11","volume":"7","author":"CM Phan","year":"2018","unstructured":"Phan CM, Weber S, Mueller J, Yee A, Jones L. A rapid extraction method to quantify drug uptake in contact lenses. Transl Vis Sci Technol. 2018;7:11.","journal-title":"Transl Vis Sci Technol"},{"key":"844_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/112067219200200306","volume":"2","author":"GT Fahy","year":"1992","unstructured":"Fahy GT, Easty DL, Collum LM, Benedict-Smith A, Hillery M, Parsons DG. Randomised double-masked trial of lodoxamide and sodium cromoglycate in allergic eye disease. A multicentre study. Eur J Ophthalmol. 1992;2:144\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"844_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0161-6420(00)00089-0","volume":"107","author":"AM Avunduk","year":"2000","unstructured":"Avunduk AM, Avunduk MC, Kapicioglu Z, Akyol N, Tavli L. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology. 2000;107:1333\u20137.","journal-title":"Ophthalmology"},{"key":"844_CR19","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/S0149-2918(02)80060-1","volume":"24","author":"CH Katelaris","year":"2002","unstructured":"Katelaris CH, Ciprandi G, Missotten L, Turner FD, Bertin D, Berdeaux G, et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther. 2002;24:1561\u201375.","journal-title":"Clin Ther"},{"key":"844_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4103\/jovr.jovr_85_17","volume":"13","author":"D Patel","year":"2018","unstructured":"Patel D, Sarala N, Datti NP. Topical olopatadine hydrochloride versus ketotifen fumarate for allergic conjunctivitis. J Ophthalmic Vis Res. 2018;13:119\u201323.","journal-title":"J Ophthalmic Vis Res"},{"key":"844_CR21","doi-asserted-by":"crossref","unstructured":"Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Acta Ophthalmol Scand Suppl. 2000:52\u20135.","DOI":"10.1034\/j.1600-0420.2000.078s230052.x"},{"key":"844_CR22","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1016\/j.clinthera.2005.09.013","volume":"27","author":"AM Avunduk","year":"2005","unstructured":"Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin Ther. 2005;27:1392\u2013402.","journal-title":"Clin Ther"},{"key":"844_CR23","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1185\/030079904125004330","volume":"20","author":"BQ Lanier","year":"2004","unstructured":"Lanier BQ, Finegold I, D'Arienzo P, Granet D, Epstein AB, Ledgerwood GL. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin. 2004;20:1227\u201333.","journal-title":"Curr Med Res Opin"},{"key":"844_CR24","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1185\/030079907X188206","volume":"23","author":"FS Mah","year":"2007","unstructured":"Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin. 2007;23:1445\u201352.","journal-title":"Curr Med Res Opin"},{"key":"844_CR25","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.2147\/OPTH.S141279","volume":"11","author":"T Mizoguchi","year":"2017","unstructured":"Mizoguchi T, Ozaki M, Ogino N. Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment. Clin Ophthalmol. 2017;11:1747\u201353.","journal-title":"Clin Ophthalmol"},{"key":"844_CR26","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/S0149-2918(02)80007-8","volume":"24","author":"GJ Berdy","year":"2002","unstructured":"Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther. 2002;24:918\u201329.","journal-title":"Clin Ther"},{"key":"844_CR27","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.clinthera.2012.04.024","volume":"34","author":"L Gong","year":"2012","unstructured":"Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, et al. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients. Clin Ther. 2012;34:1259\u201372 e1251.","journal-title":"Clin Ther"},{"key":"844_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3109\/02713683.2013.827213","volume":"39","author":"T Celik","year":"2014","unstructured":"Celik T, Turkoglu EB. Comparative evaluation of olopatadine 0.01% combined fluorometholone 0.1% treatment versus olopatadine 0.01% combined ketorolac 0.4% treatment in patients with acute seasonal allergic conjunctivitis. Curr Eye Res. 2014;39:42\u20136.","journal-title":"Curr Eye Res"},{"key":"844_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1034\/j.1600-0420.2003.00079.x","volume":"81","author":"V Yaylali","year":"2003","unstructured":"Yaylali V, Demirlenk I, Tatlipinar S, Ozbay D, Esme A, Yildirim C, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand. 2003;81:378\u201382.","journal-title":"Acta Ophthalmol Scand"},{"key":"844_CR30","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s12325-014-0155-3","volume":"31","author":"EB McLaurin","year":"2014","unstructured":"McLaurin EB, Marsico NP, Ackerman SL, Ciolino JB, Williams JM, Villanueva L, et al. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials. Adv Ther. 2014;31:1059\u201371.","journal-title":"Adv Ther"},{"key":"844_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1755-3768.2008.01265.x","volume":"87","author":"M Borazan","year":"2009","unstructured":"Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol. 2009;87:549\u201354.","journal-title":"Acta Ophthalmol"},{"key":"844_CR32","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.2147\/OPTH.S35431","volume":"6","author":"CF McCabe","year":"2012","unstructured":"McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol. 2012;6:1731\u20138.","journal-title":"Clin Ophthalmol"},{"key":"844_CR33","doi-asserted-by":"crossref","unstructured":"Secchi A, Leonardi A, Discepola M, Deschenes J, Abelson MB. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl. 2000:48\u201351.","DOI":"10.1034\/j.1600-0420.2000.078s230048.x"},{"key":"844_CR34","doi-asserted-by":"crossref","unstructured":"Secchi A, Ciprandi G, Leonardi A, Deschenes J, Abelson MB. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand Suppl. 2000:42\u20137.","DOI":"10.1034\/j.1600-0420.2000.078s230042.x"},{"key":"844_CR35","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ICO.0000000000000562","volume":"34","author":"E McLaurin","year":"2015","unstructured":"McLaurin E, Narvekar A, Gomes P, Adewale A, Torkildsen G. Phase 3 randomized double-masked study of efficacy and safety of once-daily 0.77% olopatadine hydrochloride ophthalmic solution in subjects with allergic conjunctivitis using the conjunctival allergen challenge model. Cornea. 2015;34:1245\u201351.","journal-title":"Cornea"},{"key":"844_CR36","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1517\/17425255.2014.884070","volume":"10","author":"XC Wan","year":"2014","unstructured":"Wan XC, Dimov V. Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis. Expert Opin Drug Metab Toxicol. 2014;10:543\u20139.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"844_CR37","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5935\/0004-2749.20170052","volume":"80","author":"VL Liendo","year":"2017","unstructured":"Liendo VL, Vola ME, Barreiro TP, Wakamatsu TH, Gomes JAP, Santos MSD. Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. Arq Bras Oftalmol. 2017;80:211\u20134.","journal-title":"Arq Bras Oftalmol"},{"key":"844_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5935\/0004-2749.20180059","volume":"81","author":"L Zulim","year":"2018","unstructured":"Zulim L, Nai GA, Giuffrida R, Pereira CSG, Benguella H, Cruz AG, et al. Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. Arq Bras Oftalmol. 2018;81:293\u2013301.","journal-title":"Arq Bras Oftalmol"},{"key":"844_CR39","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1167\/iovs.17-23066","volume":"59","author":"YC Liu","year":"2018","unstructured":"Liu YC, Ng XW, Teo EPW, Ang HP, Lwin NC, Chan NSW, et al. A biodegradable, sustained-released, tacrolimus microfilm drug delivery system for the management of allergic conjunctivitis in a mouse model. Invest Ophthalmol Vis Sci. 2018;59:675\u201384.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"844_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/ICO.0000000000001440","volume":"37","author":"CH Yoon","year":"2018","unstructured":"Yoon CH, Kim MK, Oh JY. Topical tacrolimus 0.03% for maintenance therapy in steroid-dependent, recurrent phlyctenular keratoconjunctivitis. Cornea. 2018;37:168\u201371.","journal-title":"Cornea"},{"key":"844_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000478704","volume":"59","author":"Q Wan","year":"2018","unstructured":"Wan Q, Tang J, Han Y, Wang D, Ye H. Therapeutic effect of 0.1% tacrolimus eye drops in the tarsal form of vernal keratoconjunctivitis. Ophthalmic Res. 2018;59:126\u201334.","journal-title":"Ophthalmic Res"},{"key":"844_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.5935\/0004-2749.20170038","volume":"80","author":"EG Muller","year":"2017","unstructured":"Muller EG, Santos MSD, Freitas D, Gomes JAP, Belfort R Jr. Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. Arq Bras Oftalmol. 2017;80:154\u20138.","journal-title":"Arq Bras Oftalmol"},{"key":"844_CR43","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/ICO.0000000000001200","volume":"36","author":"H Zanjani","year":"2017","unstructured":"Zanjani H, Aminifard MN, Ghafourian A, Pourazizi M, Maleki A, Arish M, et al. Comparative evaluation of tacrolimus versus interferon alpha-2b eye drops in the treatment of vernal keratoconjunctivitis: a randomized, double-masked study. Cornea. 2017;36:675\u20138.","journal-title":"Cornea"},{"key":"844_CR44","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ophtha.2016.11.002","volume":"124","author":"D Miyazaki","year":"2017","unstructured":"Miyazaki D, Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, et al. Steroid-sparing effect of 0.1% tacrolimus eye drop for treatment of shield ulcer and corneal epitheliopathy in refractory allergic ocular diseases. Ophthalmology. 2017;124:287\u201394.","journal-title":"Ophthalmology"},{"key":"844_CR45","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1089\/jop.2010.0177","volume":"27","author":"M Kato","year":"2011","unstructured":"Kato M, Hagiwara Y, Oda T, Imamura-Takai M, Aono H, Nakamura M. Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. J Ocul Pharmacol Ther. 2011;27:353\u201360.","journal-title":"J Ocul Pharmacol Ther"},{"key":"844_CR46","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1021\/acs.jmedchem.7b01690","volume":"61","author":"L Ripa","year":"2018","unstructured":"Ripa L, Edman K, Dearman M, Edenro G, Hendrickx R, Ullah V, et al. Discovery of a novel oral glucocorticoid receptor modulator (AZD9567) with improved side effect profile. J Med Chem. 2018;61:1785\u201399.","journal-title":"J Med Chem"},{"key":"844_CR47","first-page":"745","volume":"8","author":"M Baiula","year":"2014","unstructured":"Baiula M, Bedini A, Baldi J, Cavet ME, Govoni P, Spampinato S. Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy. Drug Des Devel Ther. 2014;8:745\u201357.","journal-title":"Drug Des Devel Ther"},{"key":"844_CR48","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1167\/iovs.10-5598","volume":"52","author":"A Shafiee","year":"2011","unstructured":"Shafiee A, Bucolo C, Budzynski E, Ward KW, Lopez FJ. In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci. 2011;52:1422\u201330.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"844_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2174\/1871528113666141106101356","volume":"13","author":"M Baiula","year":"2014","unstructured":"Baiula M, Spampinato S. Mapracorat, a novel non-steroidal selective glucocorticoid receptor agonist for the treatment of allergic conjunctivitis. Inflamm Allergy Drug Targets. 2014;13:289\u201398.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"844_CR50","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jaapos.2012.12.153","volume":"17","author":"TA Klerk de","year":"2013","unstructured":"de Klerk TA, Sharma V, Arkwright PD, Biswas S. Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS. 2013;17:305\u20136.","journal-title":"J AAPOS"},{"key":"844_CR51","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.aller.2011.08.002","volume":"40","author":"J Sanchez","year":"2012","unstructured":"Sanchez J, Cardona R. Omalizumab. An option in vernal keratoconjunctivitis? Allergol Immunopathol (Madr). 2012;40:319\u201320.","journal-title":"Allergol Immunopathol (Madr)"},{"key":"844_CR52","doi-asserted-by":"crossref","unstructured":"Taille C, Doan S, Neukirch C, Aubier M. Omalizumab for severe atopic keratoconjunctivitis. BMJ Case Rep. 2010;2010.","DOI":"10.1136\/bcr.04.2010.2919"},{"key":"844_CR53","doi-asserted-by":"crossref","unstructured":"Simpson R, Lee JK. Omalizumab as single-dose therapy for vernal keratoconjunctivitis. Ann Allergy Asthma Immunol. 2018.","DOI":"10.1016\/j.anai.2018.09.458"},{"key":"844_CR54","doi-asserted-by":"crossref","first-page":"192","DOI":"10.29262\/ram.v65i2.292","volume":"65","author":"L Santamaria","year":"2018","unstructured":"Santamaria L, Sanchez J. Long-term efficacy of omalizumab in patients with conventional treatment-resistant vernal keratoconjunctivitis. Rev Alerg Mex. 2018;65:192\u20136.","journal-title":"Rev Alerg Mex"},{"key":"844_CR55","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/pai.12737","volume":"28","author":"F Occasi","year":"2017","unstructured":"Occasi F, Duse M, Nebbioso M, De Castro G, Di Fraia M, Capata G, et al. Vernal keratoconjunctivitis treated with omalizumab: a case series. Pediatr Allergy Immunol. 2017;28:503\u20135.","journal-title":"Pediatr Allergy Immunol"},{"key":"844_CR56","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","volume":"134","author":"E Heffler","year":"2016","unstructured":"Heffler E, Picardi G, Liuzzo MT, Pistorio MP, Crimi N. Omalizumab treatment of vernal keratoconjunctivitis. JAMA Ophthalmol. 2016;134:461\u20133.","journal-title":"JAMA Ophthalmol"},{"key":"844_CR57","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/ACI.0000000000000309","volume":"16","author":"BP Bielory","year":"2016","unstructured":"Bielory BP, Shah SP, O'Brien TP, Perez VL, Bielory L. Emerging therapeutics for ocular surface disease. Curr Opin Allergy Clin Immunol. 2016;16:477\u201386.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"844_CR58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.15171\/apb.2016.046","volume":"6","author":"S Soltani","year":"2016","unstructured":"Soltani S, Zakeri-Milani P, Barzegar-Jalali M, Jelvehgari M. Comparison of different nanosuspensions as potential ophthalmic delivery systems for ketotifen fumarate. Adv Pharm Bull. 2016;6:345\u201352.","journal-title":"Adv Pharm Bull"},{"key":"844_CR59","first-page":"550","volume":"19","author":"S Soltani","year":"2016","unstructured":"\u2022\u2022 Soltani S, Zakeri-Milani P, Barzegar-Jalali M, Jelvehgari M. Design of eudragit RL nanoparticles by nanoemulsion method as carriers for ophthalmic drug delivery of ketotifen fumarate. Iran J Basic Med Sci. 2016;19:550\u201360 Novel drug formulation.","journal-title":"Iran J Basic Med Sci"},{"key":"844_CR60","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s41598-017-01487-9","volume":"7","author":"DL Pham","year":"2017","unstructured":"Pham DL, Lim KM, Joo KM, Park HS, Leung DYM, Ye YM. Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients. Sci Rep. 2017;7:1318.","journal-title":"Sci Rep"},{"key":"844_CR61","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1007\/s00417-017-3781-z","volume":"255","author":"HM Jauhonen","year":"2017","unstructured":"Jauhonen HM, Laihia J, Oksala O, Viiri J, Sironen R, Alajuuma P, et al. Topical cis-urocanic acid prevents ocular surface irritation in both IgE\u2014independent and\u2014mediated rat model. Graefes Arch Clin Exp Ophthalmol. 2017;255:2357\u201362.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"844_CR62","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/aos.12651","volume":"93","author":"HM Jauhonen","year":"2015","unstructured":"Jauhonen HM, Kari E, Pylkkanen L, Poutanen J, Laihia J, Kaarniranta K, et al. A randomized phase I clinical study of cis-urocanic acid eye drops in healthy adult subjects. Acta Ophthalmol. 2015;93:368\u201376.","journal-title":"Acta Ophthalmol"},{"key":"844_CR63","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1111\/bph.14458","volume":"175","author":"SD Dattoli","year":"2018","unstructured":"\u2022 Dattoli SD, Baiula M, De Marco R, Bedini A, Anselmi M, Gentilucci L, et al. DS-70, a novel and potent alpha4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs. Br J Pharmacol. 2018;175:3891\u2013910 Novel focus on conjunctival surface adhesion molecules to decrease allergic inflammation of the ocular surface.","journal-title":"Br J Pharmacol"},{"key":"844_CR64","doi-asserted-by":"publisher","first-page":"6116","DOI":"10.1167\/iovs.14-14075","volume":"55","author":"M Guzman","year":"2014","unstructured":"Guzman M, Sabbione F, Gabelloni ML, Vanzulli S, Trevani AS, Giordano MN, et al. Restoring conjunctival tolerance by topical nuclear factor-kappaB inhibitors reduces preservative-facilitated allergic conjunctivitis in mice. Invest Ophthalmol Vis Sci. 2014;55:6116\u201326.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"844_CR65","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1167\/iovs.15-17914","volume":"57","author":"HS Lee","year":"2016","unstructured":"Lee HS, Kwon JY, Joo CK. Topical administration of beta-1,3-glucan to modulate allergic conjunctivitis in a murine model. Invest Ophthalmol Vis Sci. 2016;57:1352\u201360.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"844_CR66","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/09273948.2016.1231330","volume":"26","author":"JY Kwon","year":"2018","unstructured":"Kwon JY, Lee HS, Joo CK. TRPV1 antagonist suppresses allergic conjunctivitis in a murine model. Ocul Immunol Inflamm. 2018;26:440\u20138.","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11882-019-0844-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-019-0844-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-019-0844-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:44:14Z","timestamp":1694652254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11882-019-0844-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["844"],"URL":"https:\/\/doi.org\/10.1007\/s11882-019-0844-8","relation":{},"ISSN":["1529-7322","1534-6315"],"issn-type":[{"value":"1529-7322","type":"print"},{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"28 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no conflicts of interest pertaining to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"16"}}